

SWIXX SIGNS €52 MILLION REVOLVING FACILITY AGREEMENT WITH UBS, CREDIT SUISSE, AND CITIBANK

SWIXX ANNOUNCEMENT NO. 37

March 4th, 2021

Baar, Switzerland – Swixx Biopharma AG of Baar, Switzerland announced the signing of a €52 million revolving facility agreement with a syndicate of three banks – UBS Switzerland AG (acting as Mandated Lead Arranger, Coordinator, Agent, Security Agent and Lender), Credit Suisse (Schweiz) AG (acting as Lender), and Citibank Europe plc, Prague Branch (acting as Lender).

“It is my great pleasure to announce this agreement with our three banking partners, commented Swixx CFO Petr Pipal. “It will help to finance working capital needs connected to the significant level of growth that we plan for next five years. Furthermore, it will strengthen Swixx’s financial offering to our Business Partners.

“The facility includes an option to request an increase of the facility up to €80 million. “This means that the revolving facility offers additional and welcome flexibility as we look at future corporate development opportunities. Finally, I would like to take this opportunity to recognize the hard work of all three banks in putting together our syndicate and thank them for their patience and support in overcoming the intricate complexities of a four-party contract.”

About Swixx Biopharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 600 employees and sales exceeding 260M Euros in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self- medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321